Trifluperidol

Trifluperidol
Clinical data
Trade names	Triperidol
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	N05AD02 (WHO) ;
Legal status
Legal status	BR: Class C1 (Other controlled substances);
Identifiers
	IUPAC name 1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]butan-1-one;
CAS Number	749-13-3 ;
PubChem CID	5567;
DrugBank	DB13552 ;
ChemSpider	5366 ;
UNII	R8869Q7R8I;
ChEMBL	ChEMBL15023 ;
CompTox Dashboard (EPA)	DTXSID4023703 ;
Chemical and physical data
Formula	C22H23F4NO2
Molar mass	409.425 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)c1cccc(c1)C3(O)CCN(CCCC(=O)c2ccc(F)cc2)CC3;
	InChI InChI=1S/C22H23F4NO2/c23-19-8-6-16(7-9-19)20(28)5-2-12-27-13-10-21(29,11-14-27)17-3-1-4-18(15-17)22(24,25)26/h1,3-4,6-9,15,29H,2,5,10-14H2 ; Key:GPMXUUPHFNMNDH-UHFFFAOYSA-N ;

Trifluperidol is a typical antipsychotic of the butyrophenone chemical class. It has general properties similar to those of haloperidol, but is considerably more potent by weight, and causes relatively more severe side effects, especially tardive dyskinesia and other extrapyramidal effects. It is used in the treatment of psychoses including mania and schizophrenia. It was discovered at Janssen Pharmaceutica in 1959.